A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma

Salvatore Paiella, Giuseppe Malleo, Nicola Simoni, Renato Micera, Stefania Guariglia, Carlo Cavedon, Giovanni Marchegiani, Alessandro Esposito, Luca Landoni, Luca Casetti, Massimiliano Tuveri, Michele Milella, Erica Secchettin, Gessica Manzini, Chiara Bovo, Matteo De Pastena, Martina Fontana, Roberto Salvia, Renzo Mazzarotto, Claudio Bassi, Salvatore Paiella, Giuseppe Malleo, Nicola Simoni, Renato Micera, Stefania Guariglia, Carlo Cavedon, Giovanni Marchegiani, Alessandro Esposito, Luca Landoni, Luca Casetti, Massimiliano Tuveri, Michele Milella, Erica Secchettin, Gessica Manzini, Chiara Bovo, Matteo De Pastena, Martina Fontana, Roberto Salvia, Renzo Mazzarotto, Claudio Bassi

Abstract

Background: The current management guidelines recommend that patients with borderline resectable pancreatic adenocarcinoma (BRPC) should initially receive neoadjuvant chemotherapy. The addition of advanced radiation therapy modalities, including stereotactic body radiation therapy (SBRT) and intraoperative radiation therapy (IORT), could result in a more effective neoadjuvant strategy, with higher rates of margin-free resections and improved survival outcomes.

Methods/design: In this single-center, single-arm, intention-to-treat, phase II trial newly diagnosed BRPC will receive a "total neoadjuvant" therapy with FOLFIRINOX (5-fluorouracil, irinotecan and oxaliplatin) and hypofractionated SBRT (5 fractions, total dose of 30 Gy with simultaneous integrated boost of 50 Gy on tumor-vessel interface). Following surgical exploration or resection, IORT will be also delivered (10 Gy). The primary endpoint is 3-year survival. Secondary endpoints include completion of neoadjuvant treatment, resection rate, acute and late toxicities, and progression-free survival. In the subset of patients undergoing resection, per-protocol analysis of disease-free and disease-specific survival will be performed. The estimated sample size is 100 patients over a 36-month period. The trial is currently recruiting.

Trial registration: NCT04090463 at clinicaltrials.gov.

Keywords: Intraoperative radiotherapy (IORT); Locally advanced pancreatic cancer; Neoadjuvant therapy; Pancreatic cancer; Stereotactic body radiation therapy (SBRT).

Conflict of interest statement

none.

References

    1. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB, 3rd, Binder E, Cardin DB, Cha C, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(8):1028–1061. doi: 10.6004/jnccn.2017.0131.
    1. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–1825. doi: 10.1056/NEJMoa1011923.
    1. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi: 10.1056/NEJMoa1304369.
    1. Maggino L, Malleo G, Marchegiani G, Viviani E, Nessi C, Ciprani D, Esposito A, Landoni L, Casetti L, Tuveri M, et al. Outcomes of primary chemotherapy for borderline Resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154(10):932-42. 10.1001/jamasurg.2019.2277.
    1. Tienhoven GV, Versteijne E, Suker M, Groothuis KBC, Busch OR, Bonsing BA, Hingh IHJTd, Festen S, Patijn GA, Vos-Geelen Jd et al: Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. J Clin Oncol 2018, 36(18_suppl):LBA4002.
    1. Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, et al. Total Neoadjuvant therapy with FOLFIRINOX followed by individualized Chemoradiotherapy for borderline Resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963–969. doi: 10.1001/jamaoncol.2018.0329.
    1. Jiang W, Haque W, Verma V, Butler EB, Teh BS. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma. Acta Oncol. 2019;58(9):1259–1266. doi: 10.1080/0284186X.2019.1631472.
    1. Mellon EA, Strom TJ, Hoffe SE, Frakes JM, Springett GM, Hodul PJ, Malafa MP, Chuong MD, Shridhar R. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer. J Gastrointest Oncol. 2016;7(4):547–555. doi: 10.21037/jgo.2016.03.15.
    1. Rajagopalan MS, Heron DE, Wegner RE, Zeh HJ, Bahary N, Krasinskas AM, Lembersky B, Brand R, Moser AJ, Quinn AE, et al. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Radiat Oncol. 2013;8:254. doi: 10.1186/1748-717X-8-254.
    1. Moningi S, Dholakia AS, Raman SP, Blackford A, Cameron JL, Le DT, De Jesus-Acosta AM, Hacker-Prietz A, Rosati LM, Assadi RK, et al. The role of stereotactic body radiation therapy for pancreatic Cancer: a single-institution experience. Ann Surg Oncol. 2015;22(7):2352–2358. doi: 10.1245/s10434-014-4274-5.
    1. Shaib WL, Hawk N, Cassidy RJ, Chen Z, Zhang C, Brutcher E, Kooby D, Maithel SK, Sarmiento JM, Landry J, et al. A phase 1 study of stereotactic body radiation therapy dose escalation for borderline Resectable pancreatic Cancer after modified FOLFIRINOX (NCT01446458) Int J Radiat Oncol Biol Phys. 2016;96(2):296–303. doi: 10.1016/j.ijrobp.2016.05.010.
    1. Simoni N, Micera R, Paiella S, Guariglia S, Zivelonghi E, Malleo G, Rossi G, Addari L, Giuliani T, Pollini T, et al. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma. Clin Oncol (R Coll Radiol). 2021;33(1):e31-8. 10.1016/j.clon.2020.06.019.
    1. Calvo FA, Asencio JM, Roeder F, Krempien R, Poortmans P, Hensley FW, Krengli M. ESTRO IORT task force/ACROP recommendations for intraoperative radiation therapy in borderline-resected pancreatic cancer. Clin Transl Radiat Oncol. 2020;23:91–99. doi: 10.1016/j.ctro.2020.05.005.
    1. Palta M, Willett C, Czito B. The role of intraoperative radiation therapy in patients with pancreatic cancer. Semin Radiat Oncol. 2014;24(2):126–131. doi: 10.1016/j.semradonc.2013.11.004.
    1. Cai S, Hong TS, Goldberg SI, Fernandez-del Castillo C, Thayer SP, Ferrone CR, Ryan DP, Blaszkowsky LS, Kwak EL, Willett CG, et al. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer. 2013;119(23):4196–4204. doi: 10.1002/cncr.28329.
    1. Yamaguchi K, Kobayashi K, Ogura Y, Nakamura K, Nakano K, Mizumoto K, Tanaka M. Radiation therapy, bypass operation and celiac plexus block in patients with unresectable locally advanced pancreatic cancer. Hepatogastroenterology. 2005;52(65):1605–1612.
    1. Chen Y, Che X, Zhang J, Huang H, Zhao D, Tian Y, Li Y, Feng Q, Zhang Z, Jiang Q, et al. Long-term results of intraoperative electron beam radiation therapy for nonmetastatic locally advanced pancreatic cancer: retrospective cohort study, 7-year experience with 247 patients at the National Cancer Center in China. Medicine (Baltimore) 2016;95(38):e4861. doi: 10.1097/MD.0000000000004861.
    1. Valentini V, Calvo F, Reni M, Krempien R, Sedlmayer F, Buchler MW, Di Carlo V, Doglietto GB, Fastner G, Garcia-Sabrido JL, et al. Intra-operative radiotherapy (IORT) in pancreatic cancer: joint analysis of the ISIORT-Europe experience. Radiother Oncol. 2009;91(1):54–59. doi: 10.1016/j.radonc.2008.07.020.
    1. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–207. doi: 10.7326/0003-4819-158-3-201302050-00583.
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45(2):228–247. doi: 10.1016/j.ejca.2008.10.026.
    1. Hishinuma S, Ogata Y, Matsui J, Ozawa I, Inada T, Shimizu H, Kotake K, Ikeda T, Koyama Y. Two cases of Cancer of the pancreatic body undergoing gastric preservation with distal Pancreatectomy combined with resection of the celiac Axis. Japanese J Gastroenterol Surg. 1991;24(11):2782–2786. doi: 10.5833/jjgs.24.2782.
    1. Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, Traverso LW, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the international study Group of Pancreatic Surgery (ISGPS) Surgery. 2007;142(5):761–768. doi: 10.1016/j.surg.2007.05.005.
    1. Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, Neoptolemos JP, Padbury RT, Sarr MG, et al. Postpancreatectomy hemorrhage (PPH): an international study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007;142(1):20–25. doi: 10.1016/j.surg.2007.02.001.
    1. Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M, Allen P, Andersson R, Asbun HJ, Besselink MG, et al. The 2016 update of the international study group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery. 2017;161(3):584–591. doi: 10.1016/j.surg.2016.11.014.
    1. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213. doi: 10.1097/.
    1. Brookmyer R, Crowley JJ. A confidence interval for the median survival time. Biometrics. 1982;38:29–41. doi: 10.2307/2530286.
    1. U.S. Department of Health and Human Services: https://www.eortcbe/services/doc/ctc/CTCAE_403_2010-06-14_QuickReference_5x7pdf Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0, Published: May 28, 2009 (v4.03: June 14, 2010),
    1. Harrison JM, Wo JY, Ferrone CR, Horick NK, Keane FK, Qadan M, Lillemoe KD, Hong TS, Clark JW, et al. Intraoperative radiation therapy (IORT) for borderline Resectable and locally advanced pancreatic ductal adenocarcinoma (BR/LA PDAC) in the era of modern Neoadjuvant treatment: short-term and long-term outcomes. Ann Surg Oncol. 2019. 10.1245/s10434-019-08084-2 Online ahead of print.
    1. Marchegiani G, Andrianello S, Nessi C, Sandini M, Maggino L, Malleo G, Paiella S, Polati E, Bassi C, Salvia R. Neoadjuvant therapy versus upfront resection for pancreatic Cancer: the actual Spectrum and clinical burden of postoperative complications. Ann Surg Oncol. 2018;25(3):626–637. doi: 10.1245/s10434-017-6281-9.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel